	US 12,257,295 B2
	Saccharide-polypeptide conjugate compositions and methods of use thereof
Bruce D. Forrest, South Nyack, NY (US); and Jack D. Love, Tampa, FL (US)
Assigned to Pogona, LLC, South Nyack, NY (US)
Appl. No. 16/753,597
Filed by Pogona, LLC, South Nyack, NY (US)
PCT Filed Oct. 4, 2018, PCT No. PCT/US2018/054391 § 371(c)(1), (2) Date Apr. 3, 2020, PCT Pub. No. WO2019/070994, PCT Pub. Date Apr. 11, 2019.
Claims priority of provisional application 62/732,260, filed on Sep. 17, 2018.
Claims priority of provisional application 62/568,164, filed on Oct. 4, 2017.
Prior Publication US 2020/0330579 A1, Oct. 22, 2020
Int. Cl. A61K 39/09 (2006.01); A61K 9/08 (2006.01); A61K 39/00 (2006.01); A61K 39/39 (2006.01); A61K 45/06 (2006.01); A61K 47/10 (2017.01); A61K 47/18 (2017.01); A61K 47/26 (2006.01)

CPC A61K 39/092 (2013.01) [A61K 9/08 (2013.01); A61K 39/39 (2013.01); A61K 47/10 (2013.01); A61K 47/183 (2013.01); A61K 47/26 (2013.01); A61K 2039/54 (2013.01); A61K 2039/545 (2013.01); A61K 2039/55505 (2013.01); A61K 2039/6037 (2013.01); A61K 45/06 (2013.01)]

20 Claims

1. A pharmaceutical composition comprising a plurality of immunogenic saccharide-polypeptide conjugates, each comprising individually a capsular polysaccharide, fragment thereof, or combination thereof conjugated to a polypeptide, wherein each of the capsular polysaccharides, fragments thereof, or combinations thereof is from a Streptococcus pneumoniae serotype; wherein the Streptococcus pneumoniae serotypes in the plurality of immunogenic saccharide-polypeptide conjugates comprise at least serotypes 6C, 8, 9N, 10A, 11A, 12F, 15A, 20B, 22F, 23A, 23B, 24F, 33F, and 35B; and

wherein the fragment or fragments of the capsular polysaccharide is a monosaccharide, a disaccharide, a trisaccharide, a tetrasaccharide, a pentasaccharide, a hexasaccharide, or an oligosaccharide.